Founded Year
2011Stage
Series D - IV | AliveTotal Raised
$177.46MLast Raised
$39M | 9 mos agoResearch containing Calysta
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Calysta in 1 CB Insights research brief, most recently on Aug 9, 2021.
Expert Collections containing Calysta
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Calysta is included in 4 Expert Collections, including Vitamin & Supplement Startups.
Vitamin & Supplement Startups
636 items
Synthetic Biology
305 items
Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.
Food & Beverage
2,791 items
Alternative Proteins Startups
366 items
This Collection includes B2B and B2C companies developing alternatives to animal-derived proteins, including plant-based meat, dairy alternatives, lab-grown or cultured meat, and fermented proteins.
Calysta Patents
Calysta has filed 45 patents.
The 3 most popular patent topics include:
- Biofuels
- Chemical processes
- Fluid dynamics
Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
1/28/2020 | 5/17/2022 | Chemical processes, Waste treatment technology, Biofuels, Fluid dynamics, Industrial gases | Grant |
Application Date | 1/28/2020 |
---|---|
Grant Date | 5/17/2022 |
Title | |
Related Topics | Chemical processes, Waste treatment technology, Biofuels, Fluid dynamics, Industrial gases |
Status | Grant |
Latest Calysta News
Jan 25, 2022
January 25, 2022 09:00 AM Eastern Standard Time SAN MATEO, Calif.--( BUSINESS WIRE )-- Calysta, Inc. World-leading alternative protein producer, Calysta, has signaled its future intentions with the appointment of Dr Lori Giver, as Chief Science and Sustainability Officer. Dr Giver first joined Calysta in 2013 as Vice President, Biological Engineering, before being appointed Vice President, Research and Development in 2019. In her new role, Lori will join the executive team and will play a key role in fulfilling Calysta’s ongoing commitment to the highest levels of sustainability. Welcoming Lori into her new role, Calysta’s President, CEO and Co-Founder, Dr Alan Shaw, said: “This is a very important appointment for Calysta. Lori has played a pivotal role in our story so far and takes up this new position at a very exciting time for the business, with our first commercial-scale production facility to open in China later this year. “Producing a sustainable protein that has no impact on biodiversity is a huge priority for us and this appointment underlines our determination to lower our footprint even further and fulfil our ongoing mission of making more from less.” Like Alan Shaw, Dr Giver came to Calysta from Codexis, where she held a number of positions including Vice President of Systems Biology, Senior Director of Technology and Innovation, and Manager of Market Development. Lori completed post-doctoral studies with 2018 Nobel Prize for Chemistry winner Dr Frances Arnold. She is an author on numerous scientific publications and over 50 patents and patent applications. On her appointment, Dr Giver said: “Calysta’s mission is to make more from less and I am passionate about fulfilling that ambition, which is why this new role is so exciting. “By 2050 there will be two billion more people to feed on planet earth, but many of our existing food production techniques are unsustainable. The status quo cannot continue. We must strive to produce lower impact foods and feeds if we are to meet global demand. Calysta has a big role to play in addressing this and I will be working hard to improving our sustainability profile even further for current and future products from our proprietary fermentation platform.” Calysta is developing a family of natural, sustainable and traceable feed ingredients for fish, livestock and pets, produced by fermenting natural gas with a naturally occurring bacteria. It requires no arable land, uses no plant or animal matter in its production and uses very little water, supporting global food security and helping feed an increasing population in a sustainable way. The first of these products, FeedKind® protein, is tailored for the aquaculture and livestock markets. Calysta’s 50/50 joint venture with Adisseo, Calysseo, is in the process of building the world’s first FeedKind commercial production facility in Chongqing, China, with 20,000 tonnes to come onto the market this year, increasing to 80,000 tonnes shortly thereafter. Investors in Calysta include bp, Adisseo, Temasek, AquaSpark, Mitsui and Cargill. For more information about Calysta, visit www.Calysta.com . Join the newsletter at www.FeedKind.com . About Calysta Calysta, Inc. , San Mateo, CA, is a biotechnology company working towards a future where the world’s growing population has guaranteed food security. Calysta’s aim is to make more from less by fermenting natural gas to create new feed and food products, creating sustainable, high value nutritional ingredients that don’t interfere with the human food chain. FeedKind®, is made using very little water and no agricultural land by fermenting natural gas, an abundant source of energy, to create a safe, nutritious, traceable and affordable protein. Produced via a natural fermentation, it is non-GMO, price competitive with existing sources of protein and produced to the highest quality standards. FeedKind has been commercially validated through extensive customer trials in aquaculture and agriculture. Contacts
Calysta Web Traffic
Calysta Rank
When was Calysta founded?
Calysta was founded in 2011.
Where is Calysta's headquarters?
Calysta's headquarters is located at 1140 O'Brien Drive, Menlo Park.
What is Calysta's latest funding round?
Calysta's latest funding round is Series D - IV.
How much did Calysta raise?
Calysta raised a total of $177.46M.
Who are the investors of Calysta?
Investors of Calysta include Progress Software, Gotham Ventures, Threshold Ventures and Partech Partners.
Who are Calysta's competitors?
Competitors of Calysta include String Bio and 1 more.
You May Also Like

Ynsect has developed Entoraffinerie for the nutritional and green chemistry markets. The company uses insects to bioconvert organic substrates, such as cereal byproducts, and turns those insects into a sustainable nutrient resource for agro-industries and bioactive compounds for green chemistry.
String Bio converts methane, a waste gas responsible for much of livestock production's greenhouse gas emissions, into proteins that can be used in animal feed.
Molofeed has developed a high-quality larval feed for marine finfish and shrimp based on proprietary micro-encapsulation technology that makes it possible to include pre-digested and other water-soluble components in a capsule, and slow-release nutrients after feeding. The technology has several additional potential applications, including acting as a delivery system for bioactive peptides, immunostimulants, and probiotics.
Biomar is a contract research group. Biomar is a a Spanish based contract research organization specializing in microbial fermentation.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.